<DOC>
	<DOCNO>NCT00496015</DOCNO>
	<brief_summary>The purpose trial ass rate febrile reaction follow co-administration booster dose pneumococcal conjugate vaccine standard infant vaccine lower paracetamol give prophylactically assess impact pneumococcal conjugate vaccine pneumococcal H. influenzae nasopharyngeal carriage compare control group receive meningococcal conjugate vaccine ( GSK134612 ) . This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = NCT00370318 ) .</brief_summary>
	<brief_title>Prophylactic Antipyretic Treatment Children Receiving Booster Dose Pneumococcal Conjugate Vaccine GSK1024850A</brief_title>
	<detailed_description>The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Antipyretics</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female , include , 1215 month age time vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Subjects unprimed group • A male female previously participate study 107017 receive 3 dos pneumococcal conjugate vaccine GSK1024850A . For subject : Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Indication , specify protocol , prophylactic antipyretic treatment . Use investigational nonregistered product ( drug vaccine ) study vaccine within one month precede dose study vaccine , plan use entire study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month prior dose study vaccine . Planned administration/administration vaccine foreseen study protocol , period start one month dose study vaccine one month dose study vaccine . History , intercurrent , diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b disease . History allergic disease reaction likely exacerbate component vaccine . History seizure ( criterion apply subject single , uncomplicated febrile convulsion past ) progressive neurological disease . Acute disease time enrolment . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Administration immunoglobulins and/or blood product within three month precede administration dose study vaccine plan administration study period . Subjects parent history atopia . Subject receive systemic antibiotic therapy acute illness within 24 hour prior vaccination . Subject likely receive antipyretic treatment result concomitant illness treat paracetamol within past 24 hour . DTPaHBVIPV/Hib vaccine : Known hypersensitivity previous administration diphtheria , tetanus , pertussis , polio , hepatitis B Hib vaccine component vaccine . Encephalopathy . As vaccine , administration DTPaHBVIPV/Hib postpone subject suffer acute mild , moderate severe illness . For subject APAP , APNAP NAP group : • Administration pneumococcal , diphtheria , tetanus , pertussis , polio , hepatitis B and/or Haemophilus influenzae type b vaccine allow use study 107017 . For subject APAP group : • Subject contraindication treatment paracetamol . For subject unprimed group : Previous vaccination meningococcal polysaccharide vaccine serogroup A , C , W135 and/or Y . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroups A , C , W135 and/or Y . Planned administration hepatitis B vaccine foreseen study protocol period start one month dose study vaccine study end . Previous vaccination tetanus toxoid contain vaccine include T , DTP , DT , DTPIPV , DTPHBVIPV HibTT vaccine six month prior study entry . History meningococcal disease due serogroup A , C , W , Y . Administration pneumococcal vaccine since birth . Full vaccination history since birth available .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Streptococcus Pneumoniae Vaccines</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>Carriage</keyword>
	<keyword>Prophylactic antipyretic</keyword>
	<keyword>Safety</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Fever</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Booster vaccination</keyword>
</DOC>